Thomas James Curnock
Known title: Chief Risk OfficerCIK: 0001756667
Associated companies
Transaction History
| GLRE | ▲ Buy | Grant | 9,158 | $0 | 3/13/2026 | View on chart |
| GLRE | ▼ Sell | Open Market | 6,552 | $0 | 3/9/2026 | View on chart |
| GLRE | ▼ Sell | Open Market | 9,942 | $125K | 11/7/2025 | View on chart |
| GLRE | ▼ Sell | Open Market | 11,500 | $149K | 8/8/2025 | View on chart |
| GLRE | ▲ Buy | Grant | 8,777 | $0 | 3/14/2025 | View on chart |
| GLRE | ▼ Sell | Open Market | 32,946 | $0 | 3/10/2025 | View on chart |
| GLRE | ▲ Buy | Grant | 8,772 | $0 | 3/15/2024 | View on chart |
| GLRE | ▲ Buy | Grant | 49,846 | $0 | 3/15/2023 | View on chart |
| GLRE | ▲ Buy | Grant | 71,991 | $0 | 3/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Greenlight Capital Q2 Letter and Valuation Analysis
Greenlight Capital released its Q2 2026 letter, outlining recent performance and strategy. A SeekingAlpha piece notes the company’s book value is 0.7x, suggesting a low valuation until ROE is examined. These reports give a clearer view of the firm’s fundamentals and potential upside.
Greenlight Capital Q2 Letter and Valuation Analysis. Greenlight Capital released its Q2 2026 letter, outlining recent performance and strategy. A SeekingAlpha piece notes the company’s book value is 0.7x, suggesting a low valuation until ROE is examined. These reports give a clearer view of the firm’s fundamentals and potential upside.